Management of Gout by Ayurvedic Drug
Phase 2
Not yet recruiting
- Conditions
- Health Condition 1: M109- Gout, unspecified
- Registration Number
- CTRI/2020/10/028225
- Lead Sponsor
- Government PG Ayurveda College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
patients presenting with classical sign and symptoms of Vatarakta
patients of Hyperuricemia with Gouty arthritis
Exclusion Criteria
patients associated with metabolic disorder and systemic disease
patients of autoimmune joint disorder except RA
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method relief in sign and symptoms of vataraktaTimepoint: 30 days
- Secondary Outcome Measures
Name Time Method improve quality of life of patients suffering from vataraktaTimepoint: 45 days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Anshumati Kwath's therapeutic effects on uric acid metabolism in gout (M109)?
How does Anshumati Kwath compare to conventional urate-lowering therapies like allopurinol in phase II gout trials?
Which biomarkers (e.g., serum urate, CRP, IL-6) predict response to Anshumati Kwath in Vatarakta (gout) patients?
What adverse events are associated with Anshumati Kwath in phase II studies, and how do they compare to Ayurvedic formulations for gout?
Are there synergistic effects of Anshumati Kwath with other herbal compounds (e.g., Guggulu, Shilajit) in managing gouty arthritis?